Home > Blog > Successful dmc services for complex hematologic cancer trial

Successful DMC Services for Complex Hematologic Cancer Trial

Clinical Trial Regulations Regulatory Consulting Regulatory Submissions

Learn how Veristat's expert biostatistics team worked with a longstanding global biopharma sponsor to navigate complex Data Monitoring Committee (DMC) requirements for a challenging hematologic cancer trial. Collaborative efforts led to successful trial progression and maintained data integrity throughout all study phases.

A global biopharmaceutical company specializing in cell therapies contacted  Veristat for support with an ongoing Phase 3 clinical trial for the treatment of relapsed refractory multiple myeloma. The study aimed to establish the efficacy and safety of their novel therapy in over 500 patients with this aggressive form of blood cancer.

In this piece, learn how Veristat's multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including:

  • Complex statistical design and analysis requirements
  • Intensive DMC reporting and communication needs
  • Multiple interim analyses and sample size re-estimation

DOWNLOAD

 

6 min read

Accelerating Patient-Centric Clinical Trials Through Science-Based Planning, Delivery and Support

May 7, 2025  Veristat Events

With 90 percent of clinical trials failing to reach completion, sponsors need innovative approaches that blend...

2 min read

ASCO Annual Meeting

Apr 23, 2025  Veristat Events

Meet Veristat at the 2025 ASCO Annual Meeting 

Advancing Oncology Therapies for Patients in Need 

Veristat is proud to...